Wird geladen...

Evaluation of a reductively activated duocarmycin prodrug against murine and human solid cancers

In treating cancer with clinically approved chemotherapies, the high systemic toxicity and lack of selectivity for malignant cells often result in an overall poor response rate. One pharmacological approach to improve patient response is to design targeted therapies that exploit the cancer milieu by...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Vielhauer, George A., Swink, Megan, Parelkar, Nikhil K., Lajiness, James P., Wolfe, Amanda L., Boger, Dale
Format: Artigo
Sprache:Inglês
Veröffentlicht: Landes Bioscience 2013
Schlagworte:
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3813569/
https://ncbi.nlm.nih.gov/pubmed/23760495
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.24348
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!